Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06471647 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Drugs on Stress Memories
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT06471647 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 36 participants.
The verdict
NCT06471647, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
There is evidence that cannabinoids, including delta-9-tetrahydrocannabinol (THC), reduce responses to acute stress and fear-related stimuli, but few studies have examined the effects of THC on memories of stressful experiences. The researchers hypothesize that THC will attenuate behavioral and physiological responses to negative valence stimuli, including memories of aversive experiences.
Interventions
- DRUG Placebo
- DRUG delta-9-tetrahydrocannabinol (THC) (5)
- DRUG delta-9-tetrahydrocannabinol (THC) (10)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-03-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06471647
The ClinicalTrials.gov registry entry for NCT06471647 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06471647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06471647 about?
NCT06471647 is a clinical study titled "Effects of Drugs on Stress Memories". There is evidence that cannabinoids, including delta-9-tetrahydrocannabinol (THC), reduce responses to acute stress and fear-related stimuli, but few studies have examined the effects of THC on memories of stressful experiences. The researchers hypothesize that THC will attenuate behavioral and phys...
What is the current status of trial NCT06471647?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2024-07-01. Estimated completion is 2025-03-25.
What interventions are being tested in trial NCT06471647?
The interventions under investigation include: Placebo (DRUG), delta-9-tetrahydrocannabinol (THC) (5) (DRUG), delta-9-tetrahydrocannabinol (THC) (10) (DRUG).
Who is sponsoring clinical trial NCT06471647?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.